DUBLIN, Ireland and MELBOURNE, Australia, June 10, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced that Dr. Mark Heffernan, Nexvet's Chief Executive Officer, is scheduled to present at the JMP Securities Life Sciences Conference 2015 in New York on Tuesday, June 23 at 11:00AM EDT. Dr. Heffernan will provide an overview of Nexvet's pioneering developments in the field of companion animal biologic therapies, including 100% species-specific monoclonal antibody therapies for chronic conditions.
A live webcast of the presentation can be accessed by visiting the investor relations section of the Nexvet website at http://ir.nexvet.com. A replay of the webcast will be archived for at least 30 days following the presentation.
About Nexvet (www.nexvet.com)
Nexvet is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet's proprietary PETization™ platform is designed to rapidly create monoclonal antibodies ("mAbs") that are recognized as "self" or "native" by an animal's immune system, a property Nexvet refers to as "100% species-specificity." Nexvet's product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.
CONTACT: Further information: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 105 email@example.com Media Lynn Granito Berry & Company Public Relations +1 212-253-8881 firstname.lastname@example.org
Source:Nexvet Biopharma plc